Trial · NCT07570823
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT07570823, Phase 3, Recruiting, Sinocelltech Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Trials, record NCT07570823. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07570823
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT number
- NCT07570823
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 101 participants, estimated
- Lead sponsor
- Sinocelltech Ltd.
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- SCTB35 injection, Rituxumab, Gemcitabine, Oxaliplatin
- First posted
- 2026-05-06
- Last updated
- 2026-08-13
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | Up to approximately 3 years | Treatment-emergent adverse events/serious adverse events/adverse events of special interest |
| Primary | Progression free survival (PFS) | Up to approximately 3 years | Defined as the time from the date of randomization to the date of first documentation of progression disease (PD) or the date of death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | Up to approximately 3 years | Overall survival is defined as the duration from the date of randomization to the date of the participant's death. |
| Secondary | Percentage of Participants Achieving Best Overall Response (BOR) | Up to approximately 3 years | BOR is defined as Complete Response (CR) or Partial Response (PR), determined by Lugano criteria |
| Secondary | Percentage of Participants Achieving CR | Up to approximately 3 years | Percentage of participants who achieve a CR determined per Lugano criteria. |
| Secondary | Duration of Response (DOR) | Up to approximately 3 years | DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first. |
| Secondary | Duration of Complete Response (DOCR) | Up to approximately 3 years | DOCR is defined as the time from the first occurrence of CR to disease progression or death, whichever occurs first. |
| Secondary | Time to Response (TTR) | Up to approximately 3 years | Time to response is defined for participants achieving a CR/PR as the time from starting therapy to first a CR/PR. |
| Secondary | Time to Complete Response (TTCR) | Up to approximately 3 years | Time to complete response is defined for participants achieving a CR as the time from starting therapy to first a CR. |
| Secondary | Event-Free Survival (EFS) | Up to approximately 3 years | EFS is defined as the duration from randomization to disease progression determined by Lugano criteria as assessed by the investigator, initiation of any non-protocol-specified new anti-lymphoma therapy for any reason, or death (whichever occurs first). |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07570823
GET https://conductscience.org/api/trials/v1/NCT07570823/registered